The price of sight - Ranibizumab, Bevacizumab, and the treatment of macular degeneration
Article Abstract:
The Food and Drug Administration (FDA) approved Ranibizumab on June 30, 2006, which is manufactured by Genentech and marketed as Lucentis - for the treatment of neovascular age-related macular degeneration. Genentech's Ranibizumab belongs to the same group of drug named Bevacizumab, also produced by Genentech, which is another monoclonal antibody that was used by ophthalmologists to treat patients who had neovascular macular degeneration or other chorioretinal diseases mediated by vascular endothelial growth factor.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Commercial support and continuing medical education
Article Abstract:
The majority of financial support for continuing medical education (CME) in the US comes from drug companies and other commercial entities. Total commercial support more than tripled between 1998 and 2003 from $302 million to $971 million.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The recognition and treatment of acute alcohol withdrawal. Bowel care: part 6 - administration of a suppository
- Abstracts: The arteriovenous system. Nursing action to tackle the time bomb of hypertension
- Abstracts: Gene discovery speeds progeria research. Gene discovery provides clues to cause of age-related macular degeneration
- Abstracts: Plagiarism, salami, ghostwriting and other forms of flattery. Dental education
- Abstracts: Mixed success found for avian flu vaccine. New Howard Hughes investigators named. Yuet Wai Kan, MD: Sickle cell and Thalassemia pioneer